Acumen PharmaceuticalsABOS
About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Employees: 52
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
0% more funds holding
Funds holding: 79 [Q4 2024] → 79 (+0) [Q1 2025]
3.81% less ownership
Funds ownership: 70.73% [Q4 2024] → 66.92% (-3.81%) [Q1 2025]
33% less call options, than puts
Call options by funds: $45K | Put options by funds: $67K
39% less capital invested
Capital invested by funds: $73.1M [Q4 2024] → $44.8M (-$28.3M) [Q1 2025]
58% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 33
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
UBS Colin Bristow | 277%upside $4 | Buy Maintained | 28 Mar 2025 |
HC Wainwright & Co. Andrew Fein | 938%upside $11 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ABOS published over the past 30 days









